EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES

Subrata Ghosh  1     Marc Ferrante  2     Britta Siegmund  3     Takehiro Arai  4     Walter Reinisch  5     Naomi Martin  6     Joanne Rizzo  6     Kristina Kligys  6     Yafei Zhang  6     Javier Zambrano  6     Jasmina Kalabic  7     David P. Hudesman  8     Edouard Louis  9    
1 University College Cork, Birmingham, Ireland
2 University Hospitals Leuven, Leuven, Belgium
3 Charité - Universitätsmedizin Berlin, Berlin, Germany
4 Tokatsu‐Tsujinaka Hospital, Chiba, Japan
5 Medical University of Vienna, Wien, Austria
6 AbbVie, Inc, North Chicago, United States
7 AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
8 Inflammatory Bowel Disease Center, New York, United States
9 CHU Liège and Liège University, Liège, Belgium

Topic
Endoscopy, Histopathology, IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing